AL
REGN icon

Aspiriant LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Aspiriant LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Buy
465
+135
+41% +$91.9K 0.01% 323
2026
Q1 		$255K Sell
330
-69
-17% -$52.8K 0.01% 304
2025
Q4 		$308K Buy
+399
New +$271K 0.01% 273
2025
Q2 		– Sell
-364
Closed -$231K – 315
2025
Q1 		$231K Sell
364
-23
-6% -$15.8K 0.01% 271
2024
Q4 		$276K Buy
387
+49
+14% +$41.1K 0.01% 242
2024
Q3 		$355K Sell
338
-14
-4% -$15.6K 0.01% 218
2024
Q2 		$370K Sell
352
-46
-12% -$44.6K 0.02% 210
2024
Q1 		$383K Hold
398
– – 0.02% 222
2023
Q4 		$350K Buy
398
+56
+16% +$46.1K 0.02% 225
2023
Q3 		$281K Buy
+342
New +$269K 0.01% 234

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Aspiriant LLC's REGN Position: Q2 2026 in Review

Aspiriant LLC increased its Regeneron Pharmaceuticals (REGN) stake by 41% in Q2 2026, buying an estimated $91.9K and bringing the position to 465 shares worth $290K. The position accounts for 0.01% of the portfolio, ranked #323.

Aspiriant LLC first reported a position in REGN in Q3 2023 and has held it in 10 quarters since. The position peaked at $383K in Q1 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Aspiriant LLC held 465 shares of Regeneron Pharmaceuticals worth $290K as of Q2 2026.
  • Aspiriant LLC bought 135 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $91.9K.
  • Regeneron Pharmaceuticals made up 0.01% of Aspiriant LLC's portfolio in Q2 2026, its #323 holding.
  • Aspiriant LLC first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • Aspiriant LLC's Regeneron Pharmaceuticals position peaked at $383K in Q1 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Aspiriant LLC's 13F filing for Q2 2026, filed 20 Jul 2026.